Ashwagandha (Withania somnifera)

Ingredient context

Ashwagandha's adaptogenic and anti-stress effects in the general adult population are well documented. Multiple randomised, double-blind, placebo-controlled trials have found significant reductions in Perceived Stress Scale scores, improvements in sleep quality, and reductions in salivary cortisol with standardised root extract supplementation, and the herb has a long, favourable general safety record in non-pregnant, non-lactating adults.

Evidence context

The specific evidence for Ashwagandha during breastfeeding, however, is limited, and it is important to say precisely what that means. The U.S. National Library of Medicine's LactMed database, a leading reference on medication and herb safety during lactation, states plainly that no data exist on whether Withania compounds pass into breast milk, and that because of this absence of published experience, caution is warranted, particularly while nursing a newborn or preterm infant. This is not the same as evidence of harm — it is an acknowledged evidence gap, and Ayurvedic tradition has long used Ashwagandha in the postpartum period, often in combination formulas alongside Shatavari. But a pharmacist-founded brand has an obligation to state that gap rather than smooth over it. Our recommendation, and the reason CALM's own labelling carries this guidance, is that breastfeeding mothers, especially in the first several weeks with a newborn, speak with their doctor before starting CALM, and that mothers of preterm infants exercise particular caution.